Empagliflozin in Heart Failure Dialysis Patients

Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05967156

Enrollment

Registered

2023-08-01

Start date

2023-06-01

Completion date

2025-06-03

Last updated

2025-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Hemodialysis

Brief summary

Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Detailed description

Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.

Interventions

DRUGEmpagliflozin10Mg Tab

10 mg daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Heart failure on dialysis with residual renal function

Exclusion criteria

* Dialysis patients with no residual urine

Design outcomes

Primary

Measure	Time frame	Description
Brain Natriuretic Peptide	one month after administration	serum level

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026